WEST

Freeform Search

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: liposome near6 lipase

Display: 20 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences | Cases

Search History

DATE: Wednesday, July 23, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB; PLUR=YES; OP=AND			
L3	liposome near6 lipase	26	L3
L2	liposome near7 cpat near5 (n-terminal or c-terminal or fragment or component)	0	L2
L1	liposome near7 lipase near5 (n-terminal or c-terminal or fragment or component)	2	L1

END OF SEARCH HISTORY

Generate Collection | Print

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. 20020035084 . 21 Nov 01. 21 Mar 02. Pharmaceuticals and assays using enzyme subunits. Titball, Richard W., et al. 514/44; 424/146.1 A61K048/00 A61K039/395.

☐ 2. 6472365 . 16 Mar 98; 29 Oct 02. Pharmaceuticals and assays using enzyme subunits. Titball; Richard W, et al. 514/1; 424/130.1 424/134.1 424/141.1 424/152.1 514/2. A01N061/00 A01N037/18 A61K039/395.

Generate Collection | Print

Terms	Documents
liposome near7 lipase near5 (n-terminal or c-terminal or fragment or component)	2

Previous Page Next Page

Generate Collection | Print

Search Results - Record(s) 1 through 20 of 26 returned.

☐ 1. 20030059420 . 02 Feb 01. 27 Mar 03. Lipid hydrolysis therapy for atherosclerosis and related diseases. Grabowski, Gregory, et al. 424/94.6; 514/8 A61K038/46 A61K038/16.

☐ 2. 20020035084 . 21 Nov 01. 21 Mar 02. Pharmaceuticals and assays using enzyme subunits. Titball, Richard W., et al. 514/44; 424/146.1 A61K048/00 A61K039/395.

☐ 3. 20020012651 . 10 May 01. 31 Jan 02. Release of therapeutic agents in a vessel or tissue. Loeb, Marvin P.. 424/85.1; 424/130.1 424/450 424/94.1 514/44 A61K048/00 A61K038/19 A61K039/395 A61K038/43 A61K009/127.

☐ 4. 20020001614 . 09 Feb 01. 03 Jan 02. Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof. Jorgensen, Kent, et al. 424/450; 554/103 554/51 554/84 A61K009/127 C11C003/00.

☐ 5. 20010006950 . 10 Feb 99. 05 Jul 01. GENETIC VACCINE VECTOR ENGINEERING. PUNNONEN, JUHA, et al. 514/44; 435/320.1 A61K048/00.

☐ 6. 6479258 . 31 Jan 00; 12 Nov 02. Non-stochastic generation of genetic vaccines. Short; Jay M.. 435/69.1; 530/350 536/23.2. C12P021/06 C07K001/00 C07H021/04.

☐ 7. 6476243 . 27 Sep 00; 05 Nov 02. Perfluorinated esters of alkanoyl L-carnitine for the preparation of cationic lipids for the intracellular delivery of pharmacologically active compounds. Santaniello; Mose, et al. 554/121; 554/123 554/225 554/231 560/170 560/172. C07F003/06.

☐ 8. 6472365 . 16 Mar 98; 29 Oct 02. Pharmaceuticals and assays using enzyme subunits. Titball; Richard W, et al. 514/1; 424/130.1 424/134.1 424/141.1 424/152.1 514/2. A01N061/00 A01N037/18 A61K039/395.

☐ 9. 6379699 . 28 Sep 99; 30 Apr 02. Liposome having attached target-binding moiety and artherosclerotic plaque interacting moiety. Virtanen; Jorma, et al. 424/450; 424/159.1 424/160.1 424/161.1 424/178.1 424/179.1 424/193.1 424/194.1 424/94.1 424/94.2 424/94.6 424/94.61 424/94.63 435/174 435/177 435/235.1 436/528 514/44 530/812. A61K009/127 A61K038/43 A61K038/51 A61K039/395 C12N011/02.

☐ 10. 6296870 . 03 Feb 98; 02 Oct 01. Liposomes containing active agents. Needham; David, et al. 424/450; 424/1.21 424/9.321 424/9.51 424/94.3. A61K009/127 A61K009/133.

☐ 11. 6258528 . 22 Feb 99; 10 Jul 01. Signal amplification method. Carr; Frank. 435/5; 435/7.1 436/516 436/536 436/829. C12Q001/70 G01N033/53 G01N033/561 G01N033/542.

☐ 12. 6143321 . 19 Oct 98; 07 Nov 00. Liposomes containing active agents. Needham; David, et al. 424/450; 424/1.21 424/9.321 424/9.51 424/94.3. A61K009/127 A61K009/133.

☐ 13. 5882679 . 05 Aug 98; 16 Mar 99. Liposomes containing active agents aggregated with lipid surfactants. Needham; David. 424/450;. A61K009/127.

☐ 14. 5876747 . 08 Jul 92; 02 Mar 99. Liposome preferentially traveling to cardiac and skeletal muscles. Stracher; Alfred, et al. 424/450; 514/78 514/821 554/79 554/80. A61K009/127 A61K031/685.

☐ 15. 5827533 . 06 Feb 97; 27 Oct 98. Liposomes containing active agents aggregated with lipid surfactants. Needham; David. 424/450; 424/1.21 424/9.32 424/9.51. A61K009/133 A61K009/127.

☐ 16. 5766600 . 03 May 95; 16 Jun 98. Non-azo naphtalimide dyes and uses for same. Lewis; David E., et al. 424/204.1; 424/234.1 514/296. A61K039/02 A61K039/12.

☐ 17. 5665379 . 13 May 94; 09 Sep 97. Lipid particle forming matrix, preparation and use thereof. Herslof; Bengt, et al. 426/450; 264/4.1 264/4.3 424/484 424/489 424/490 424/498 424/502 428/402.2. A61K009/127 A61K009/14.

☐ 18. 5626869 . 29 Jun 95; 06 May 97. Pharmaceutical composition containing a defined lipid system. Nyqvist; H.ang.kan, et al. 424/450; 264/4.1 424/489 428/402.2. A61K009/127 A61K009/16.

☐ 19. 5565551 . 03 May 95; 15 Oct 96. Non-azo naphthalimide dyes and uses for same. Lewis; David E., et al. 530/405; 530/402 530/403 530/409. C07K001/00 C07K014/00 C07K016/00 C07K017/00 C08H001/00.

☐ 20. 5420136 . 09 Aug 93; 30 May 95. Eradication of pathogenic biological contaminants using non-azo naphthalimide dyes. Lewis; David E., et al. 514/296; 424/1.17 424/1.33 424/1.49 424/1.65 424/1.81 514/284 514/885 540/467 546/100 546/13 546/14 546/22 546/23 546/76 546/77 546/88 546/97 546/98. A61K031/435 A61K031/535 A61K031/54 A61K039/00.

Generate Collection | Print

Terms	Documents
liposome near6 lipase	26

Previous Page Next Page

Generate Collection | Print

Search Results - Record(s) 21 through 26 of 26 returned.

☐ 21. 5235045 . 19 Mar 92; 10 Aug 93. Non-azo naphthalimide dyes. Lewis; David E., et al. 534/560; 530/350 536/1.11 536/123.1 536/22.1 544/333 546/100 546/13 546/14 546/22 546/23 546/97 546/98 546/99. C07D221/18 C07D221/14 A61K031/435.

☐ 22. 5149642 . 20 Apr 90; 22 Sep 92. Process for preparing 2-acylglycerides or 1,2 or 2,3-diacylglycerides. Mazur; Adam W., et al. 435/135; 435/134 435/198. C12P007/64 C12P007/62 C12N009/20.

☐ 23. 5116745 . 19 Apr 90; 26 May 92. Process for preparing 2-acylglycerides or 1,2-diacyl diglycerides or 2,3-diacyl diglycerides. Mazur; Adam W., et al. 435/134; 435/198. C12P007/64 C12P007/62 C12N009/20.

☐ 24. 5008288 . 04 May 89; 16 Apr 91. Carnitine directed pharmaceutical agents. Stracher; Alfred, et al. 514/535; 424/450 428/402.2 514/17 514/2 514/305 514/547 514/556 514/821 530/330 530/812. A61K031/24 A61K031/44 A61K037/02 C07K017/02.

☐ 25. 4866040 . 15 Jan 87; 12 Sep 89. Aminocarnitine directed pharmaceutical agents. Stracher; Alfred, et al. 514/17; 424/450 428/402.2 514/2 514/305 514/535 514/547 514/556 514/78 514/821 530/330 930/10 930/250 930/30. A61K031/225 A61K037/02 A61K037/64 C08G069/08.

☑ 26. 4463090 . 30 Sep 81; 31 Jul 84. Cascade amplification enzyme immunoassay. Harris; Curtis C.. 435/7.7; 435/13 435/188 435/23 435/24 435/7.71 435/7.9 435/7.91 435/810 435/966 435/975 436/829. G01N033/54 C12Q001/56 C12Q001/38 C12N009/96.

Generate Collection | Print

Terms	Documents
liposome near6 lipase	26

Previous Page Next Page

```
=> d his

     (FILE 'HOME' ENTERED AT 15:50:39 ON 23 JUL 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:50:58 ON 23 JUL
     2003
L1          1739 S LIPOSOME(5A)(N-TERMINAL OR C-TERMINAL OR FRAGMENT OR COMPONEN
L2            34 S L1(5A)(THERAPEUTIC? OR PHARMACEUTIC? OR TK OR CYTOKINE OR GRO
L3            32 DUP REM L2 (2 DUPLICATES REMOVED)
L4           684 S ANTIBOD?(5A)LIPASE
L5             0 S L4 AND LYPOSOME
L6             2 S L4 AND LIPOSOME
L7             2 DUP REM L6 (0 DUPLICATES REMOVED)

=> d bib ab 1-2 l7

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2000:706946  CAPLUS
DN   133:301116
TI   Compositions and methods for regulating levels of high-density lipoprotein
     (HDL) cholesterol and apolipoprotein A-I, very-low-density lipoprotein
     (VLDL) cholesterol, and low-density lipoprotein (LDL) cholesterol
IN   Jaye, Michael; Lynch, Kevin J.; Amin, Dilip V.; Doan, Kim-anh Thi;
     Marchadier, Dawn; Maugeais, Cyrille; Rader, Daniel J.; Krawiec, John A.;
     South, Victoria J.
PA   Aventis Pharmaceuticals Products Inc., USA; The Trustees of the University
     of Pennsylvania; et al.
SO   PCT Int. Appl., 171 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2000057837      A2    20001005       WO 2000-US7870   20000324
     WO 2000057837      A3    20010125
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 2000039187      A5    20001016       AU 2000-39187    20000324
     BR 2000009333      A     20020108       BR 2000-9333     20000324
     EP 1171078         A2    20020116       EP 2000-918362   20000324
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002540127      T2    20021126       JP 2000-607588   20000324
     NO 2001004657      A     20011121       NO 2001-4657     20010925
PRAI US 1999-277401     A2    19990326
     WO 2000-US7870     W     20000324
AB   Compns. and methods are disclosed for raising the level of HDL cholesterol
     and apolipoprotein A-I in a patient and for lowering the levels of VLDL
     cholesterol and LDL cholesterol in a patient, including compns. and
     methods which affect the expression of a gene, LIPG, which encodes a
     lipase that is a member of the triacylglycerol lipase family or which
     affect the activity of the enzyme.

L7   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   1999:64709  CAPLUS
DN   130:138298
```

TI Decreased fat absorption with an anti-**lipase antibody**
IN Pimentel, Julio L.
PA Ximed Group Plc, UK
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9902187	A1	19990121	WO 1998-GB1998	19980706
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9882326	A1	19990208	AU 1998-82326	19980706
	EP 1001809	A1	20000524	EP 1998-932392	19980706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	BR 9815504	A	20001128	BR 1998-15504	19980706
	JP 2001525314	T2	20011211	JP 2000-501777	19980706
	NO 2000000052	A	20000302	NO 2000-52	20000106
	BG 104061	A	20001130	BG 2000-104061	20000106
PRAI	US 1997-888202	A	19970707		
	US 1997-882202	A	19970707		
	WO 1998-GB1998	W	19980706		

AB A method for the decrease of fat absorption in any animal, wherein the animal is fed an **antibody** produced against **lipase**, an enzyme which is required for fat absorption. Avian egg-derived anti-**lipase antibodies** are disclosed for treating obesity in a mammal or an avian. Also, avian egg-derived antibodies (IgYs) against gastrointestinal enzyme such as amylase, trypsin, chymotrypsin, protease and other enzyme or antigen are used for reducing absorption of nutrients such as proteins, carbohydrates and lipids. These antibodies are mixed in food (concd., additive-added, refrigerated or frozen food) for human or animal consumption.

=>

```
=> d his

     (FILE 'HOME' ENTERED AT 15:50:39 ON 23 JUL 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:50:58 ON 23 JUL
     2003
L1          1739 S LIPOSOME(5A)(N-TERMINAL OR C-TERMINAL OR FRAGMENT OR COMPONEN
L2            34 S L1(5A)(THERAPEUTIC? OR PHARMACEUTIC? OR TK OR CYTOKINE OR GRO
L3            32 DUP REM L2 (2 DUPLICATES REMOVED)
L4           684 S ANTIBOD?(5A)LIPASE
L5             0 S L4 AND LYPOSOME
L6             2 S L4 AND LIPOSOME
L7             2 DUP REM L6 (0 DUPLICATES REMOVED)
L8           875 S ANTIBOD?(8A)LIPASE
L9             2 S L8 AND LIPOSOME
L10         7532 S LIPOSOME(5A)(THERAPEUTIC? OR PHARMACEUTIC? OR TK OR CYTOKINE
L11         1033 S LIPASE(5A)(N-TERMINAL OR C-TERMINAL OR FRAGMENT OR COMPONENT)
L12            0 S L10 AND L11
L13            7 S L11 AND LIPOSOME
L14            7 DUP REM L13 (0 DUPLICATES REMOVED)

=> d bib ab 1-7 l14

L14  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2001:208507  CAPLUS
DN   134:234000
TI   Spatially-addressed lipid bilayer arrays and lipid bilayers with
     addressable confined aqueous compartments
IN   Cremer, Paul S.; Simanek, Eric E.; Yang, Tinglu
PA   The Texas A & M University System, USA
SO   PCT Int. Appl., 87 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2001020330      A1    20010322       WO 2000-US25627  20000918
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1218745          A1    20020703       EP 2000-963609   20000918
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
PRAI US 1999-154576P    P     19990917
     US 2000-564708     A     20000504
     WO 2000-US25627    W     20000918
AB   Disclosed are spatially-addressed arrays of discreet fluid lipid bilayers
     prepd. by flexible patterning methods that facilitate the
     compartmentalization of lipid membranes and aq. solns. disposed thereon
     into discreet, spatially-addressable, microarray partitions, onto specific
     and discreet locations of a substantially planar solid support.  This
     process can either be used in parallel or sequentially to pattern
     thousands of distinct membranes on a single "biochip", and to assay
     pluralities of selected analyte components contacted with the discreet
     lipid bilayer compartments for one or more target mols.  Also provided are
     biochip microarray systems and methods for their prodn. that comprise
     arrays of confined aq. compartments disposed upon such compartmentalized
```

lipid bilayers. The aq. compartments are independently addressable, thereby facilitating reagent delivery, reagent extn., anal. probe and high-throughput analyte screening methods.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:668010 CAPLUS
DN 129:306499
TI BAL C-tail drug delivery molecules
IN Tang, Jordan J. N.; Wang, Chi-Sun
PA Oklahoma Medical Research Foundation, USA
SO U.S., 16 pp., Cont.-in-part of U.S. 5,696,087.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5821226	A	19981013	US 1995-482262	19950607
	US 5696087	A	19971209	US 1994-347718	19941201
	CA 2206526	AA	19960606	CA 1995-2206526	19951201
	WO 9617054	A1	19960606	WO 1995-US15647	19951201
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9645064	A1	19960619	AU 1996-45064	19951201
	AU 707558	B2	19990715		
	EP 795011	A1	19970917	EP 1995-943643	19951201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 3007161	B2	20000207	JP 1996-519095	19951201
	JP 10510166	T2	19981006		
PRAI	US 1994-347718	A2	19941201		
	US 1995-479160	A	19950607		
	US 1995-482262	A	19950607		
	WO 1995-US15647	W	19951201		

AB Drug delivery conjugates of a BAL C-tail peptide, including all or a portion of the carboxy terminal region of human bile salt-activated lipase (BAL), conjugated to a biol. active substance are described. The C-tail peptide-drug conjugates, when orally ingested, compete with native BAL in binding to the intestinal surface, and, as a result, permit drug compns. to be delivered specifically to the intestine. Useful C-tail peptides are derivs. of the carboxy terminal region of BAL derived from all or portion of the region contg. amino acid residues 539 to 722, and have a mucin-like structure contg. at least three of the repeating proline-rich units of eleven amino acid residues each.

RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:446972 CAPLUS
DN 125:96049
TI Method and compositions containing human bile salt **lipase fragment** for reducing intestinal absorption of cholesterol
IN Tang, Jordan J. N.; Wang, Chi-Sun
PA Oklahoma Medical Research Foundation, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9617054	A1	19960606	WO 1995-US15647	19951201
	W: AU, CA, JP				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

	US 5696087	A	19971209	US 1994-347718	19941201
	US 5681819	A	19971028	US 1995-479160	19950607
	US 5821226	A	19981013	US 1995-482262	19950607
	AU 9645064	A1	19960619	AU 1996-45064	19951201
	AU 707558	B2	19990715		
	EP 795011	A1	19970917	EP 1995-943643	19951201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

	JP 3007161	B2	20000207	JP 1996-519095	19951201
	JP 10510166	T2	19981006		
PRAI	US 1994-347718	A	19941201		
	US 1995-479160	A	19950607		
	US 1995-482262	A	19950607		
	WO 1995-US15647	W	19951201		

AB Compns. derived from all or a portion of the carboxy terminal region of human bile salt-activated lipase (BAL) are described, which, when orally ingested, compete with native BAL in binding to the intestinal surface, thus reducing the physiol. role of BAL in mediating the transfer of cholesterol into the intestinal cells, and, as a result, reducing the amt. of cholesterol absorbed from the intestine into the blood stream. Useful derivs. of the carboxy terminal region of BAL are derived from all or portion of the region contg. amino acid residues 539 to 722, and have a mucin-like structure contg. at least three of the repeating proline-rich units of eleven amino acid residues each. Conjugates of the BAL peptide and biol. active substances (such as proteins, vitamins, chemotherapeutic agents, etc.) are also claimed. The C-terminus of BAL was found to be involved in binding of BAL to intestinal epithelial lining cells. Addn. of the C-terminal fragment to intestinal content released bound endogenous BAL. This fragment competitively inhibited cholesterol uptake in the rat intestine. BAL was shown to mediate uptake of triglycerides but not taurocholate in isolated rat intestinal tissue.

L14 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1986:586483 CAPLUS
DN 105:186483
TI Activation of lipoprotein lipase by N-.alpha.-palmitoyl (56-79) fragment of apolipoprotein C-II
AU Balasubramaniam, Ambikaipakan; Rechtin, Ann; Mclean, Larry R.; Jackson, Richard L.; Demel, Rudy A.
CS Merrell Dow Res. Inst., Cincinnati, OH, USA
SO Biochemical and Biophysical Research Communications (1986), 137(3), 1041-8
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English
AB The effect of apolipoprotein C-II (apoC-II) and a synthetic fragment of apoC-II corresponding to residues 56-79 on the lipoprotein lipase (LpL)-catalyzed hydrolysis of trioleoylglycerol in a monolayer of egg phosphatidylcholine and of dipalmitoylphosphatidylcholine vesicles was examd. Synthetic peptide 56-79, which does not assoc. with lipid, did not activate LpL at surface pressures >30 mN/m; apoC-II is active at .ltoreq.34 mN/m. However, acylation of the N-terminus of peptide 56-79 with palmitoyl chloride gave nearly identical LpL-activating properties as compared to apoC-II. Thus, at high surface pressures, the lipid-binding region of apoC-II (residues 44-55) plays an essential role in LpL activation.

L14 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1982:176780 CAPLUS
DN 96:176780
TI Lipoprotein **lipase** interaction with synthetic N-dansyl **fragments** of apolipoprotein C-II
AU Smith, Louis C.; Voyta, John C.; Kinnunen, Paavo K. J.; Gotto, Antonio M., Jr.; Sparrow, James T.
CS Baylor Coll. Med., Houston, TX, 77030, USA

SO Biophysical Journal (1982), 37(1), 174-5
CODEN: BIOJAU; ISSN: 0006-3495
DT Journal
LA English
AB The activation of bovine milk lipoprotein **lipase** by synthetic **fragments** of apolipoprotein C-II (apoC-II) contg. a single dansyl group (DNS) on the N-terminal residue [(apoC-II-DNS-(64-78), apoC-II-DNS-(60-78), apoC-II-DNS-(55-78), apoC-II-DNS-(50-78), and apoC-II-DNS-(43-78)] was 0, 60, 80, 90, and 100%, resp., of that produced by native apoC-II. The corresponding resp. assocn. consts. were 0.25, 1.25, 4.6, 0.5, and 2.0 .times. 106 M-1. The activation of lipoprotein lipase was detd. in the absence of a substrate. Energy transfer from apoC-II-DNS-(55-78) was abolished by guanidinium chloride. Energy transfer also occurred from the enzyme in the presence of a nonhydrolyzable substrate, single-walled vesicles of 1-oleyl-2-palmityl-2-phosphorylcholine glyceryl ether. Apparently, the enhancement of lipoprotein lipase is primarily due to direct protein-protein interactions involving residues 55-74 rather than to an effect of apoC-II on the substrate surface.

L14 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1982:487714 CAPLUS
DN 97:87714
TI Immunological studies on bovine milk lipoprotein **lipase**. Effects of Fab **fragments** on enzyme activity
AU Shirai, Kohji; Wisner, Daniel A.; Johnson, J. David; Srivastava, Laxmi S.; Jackson, Richard L.
CS Coll. Med., Univ. Cincinnati, Cincinnati, OH, 45267, USA
SO Biochimica et Biophysica Acta (1982), 712(1), 10-20
CODEN: BBACAQ; ISSN: 0006-3002
DT Journal
LA English
AB Rabbit antiserum against purified bovine milk lipoprotein lipase (I) was prepd. Immunoelectrophoresis of I gave a single precipitin line against the antibody; the line was coincident with enzyme activity. The .gamma.-globulin fraction inhibited heparin-releasable I activity of bovine arterial intima, heart, muscle, and adipose tissue. The antibody also inhibited the I activities of adipose tissue of human and pig, but not those of rat and dog. Fab fragments were prepd. by papain digestion of the .gamma.-globulin fraction. Fab fragments inhibited the I-catalyzed hydrolysis of dimyristoylphosphatidylcholine vesicles and triolein emulsions to the same extent. The Fab fragments also inhibited the lipolysis of human plasma very-low-d. lipoproteins. The change in the kinetic parameters for the I-catalyzed hydrolysis of triolein by the Fab fragments was accompanied by a 3-fold increase in Km and a 10-fold decrease in Vmax. Preincubation of I with apolipoprotein C-II, the activator protein for I, did not prevent inhibition of enzyme activity by the Fab fragments. However, preincubation with dipalmitoylphosphatidylcholine-emulsified triolein or Triton X-100-emulsified triolein had a protective effect (remaining activity 7.0 or 25.8%, resp., compared with 1.0 or 0.4% with no preincubation). The addn. of both apolipoprotein G-II and substrate prior to the incubation with the Fab fragments was assocd. with an increased protective effect against inhibition of enzyme activity; remaining activity with dipalmitoylphosphatidylcholine-emulsified triolein was 40.6% and with Triton X-100-emulsified triolein, 45.4%. Human plasma very-low-d. lipoproteins also protected against the inhibition of I activity by the Fab fragments. Apparently, the interaction of I with apolipoprotein C-II in the presence of lipids is assocd. with a conformational change in the structure of the enzyme such that the Fab fragments are less inhibitory. The consequence of a conformational change in I may be to facilitate the formation of an enzyme-triacylglycerol complex so as to enhance the rate of the I-catalyzed turnover of substrate to products.

L14 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1982:30689 CAPLUS
DN 96:30689
TI Limited trypsinolysis of porcine and equine colipases. Spectroscopic and kinetic studies
AU Rathelot, J.; Canioni, P.; Bosc-Bierne, I.; Sarda, L.; Kamoun, A.; Kaptein, R.; Cozzone, P. J.
CS Lab. Biochim., Fac. St-Charles, Marseille, 13003, Fr.
SO Biochimica et Biophysica Acta (1981), 671(2), 155-63
CODEN: BBACAQ; ISSN: 0006-3002
DT Journal
LA English
AB On mild tryptic hydrolysis of porcine and equine colipases, proteolysis occurred at the arginine5-glycine6 bond with the loss of the N-terminal pentapeptide. Studies of native and trypsin-treated colipases by CD and laser chem. induced dynamic nuclear polarization indicate that proteolysis induces conformational changes in the region of the tyrosine cluster. Expts. in the presence of phospholipid indicate that these residues are in or close to the region of the protein interacting with aggregated lipids. Kinetic studies of the reaction of bile salt-inhibited lipase with emulsified triolein in the absence and in the presence of lecithin show that tryptic hydrolysis of the protein cofactor increases its affinity for the enzyme in the presence of lipid substrate. In both cases, the apparent dissocn. const. of the lipase-colipase complex is decreased by 1 order of magnitude. The results confirm that the biol. activity of the lipase cofactor is enhanced by specific tryptic cleavage in the N-terminal region of the polypeptide and support the suggestion by B. Borgstroem et al. (1981) that the secreted form of colipase is a precursor.

=>

=> d au ti so 1-32 l3

L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Reszka, Regina; Fichtner, Iduna
TI Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
SO PCT Int. Appl., 7 pp.
CODEN: PIXXD2

L3 ANSWER 2 OF 32 MEDLINE on STN DUPLICATE 1
AU Ichihara Hideaki; Nagami Hideaki; Yamamoto Keiichi; Matsumoto Yoko; Ueoka Ryuichi
TI Chemotherapy with hybrid liposomes without any drug in vivo.
SO YAKUGAKU ZASSHI. JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, (2003 Jan) 123 (1) 25-34.
Journal code: 0413613. ISSN: 0031-6903.

L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Boni, Lawrence; Wu, Fangjun; Fennimore, Roy; Batenjany, Michael M.
TI Preparation of large liposomes by infusion into an aqueous polymer solution
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2

L3 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Cheng, Jui-Ching
TI Compositions and procedures for preventing aggregation of liposomes
SO Ger. Offen., 12 pp.
CODEN: GWXXBX

L3 ANSWER 5 OF 32 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AU Thierry, Alain R. (1)
TI Liposomal delivery system for biologically active agents.
SO Official Gazette of the United States Patent and Trademark Office Patents, (Aug. 29, 2000) Vol. 1237, No. 5, pp. No Pagination. e-file.
ISSN: 0098-1133.

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Netti, Paolo A.
TI Movement of macromolecules, particles, and cells in hydrogel.
SO Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, 2000 (2000), POLY-306 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69CLAC

L3 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Holland, John W.; Madden, Thomas D.; Cullis, Pieter R.
TI Bilayer-stabilizing components and their use in forming programmable fusogenic liposomes
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2

L3 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Mizuguchi, H.; Nakanishi, M.; Nakanishi, T.; Nakagawa, T.; Nakagawa, S.; Mayumi, T.
TI Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy
SO British Journal of Cancer (1996), 73(4), 472-6
CODEN: BJCAAI; ISSN: 0007-0920

L3 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Makino, Kimiko
TI Stabilization of liposomes for controlled release
SO Fragrance Journal (1996), (4), 85-93

CODEN: FUJAD7; ISSN: 0288-9803

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Helmus, Michael N.; Tolkoff, M. Joshua; Raleigh, Carol L.
TI Manufacture of medical devices with tissue exposure to release an agent from reservoir
SO U.S., 16 pp. Cont. of U.S. Ser. No. 525,339, abandoned.
CODEN: USXXAM

L3 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Gursel, M.; Hasirci, V.
TI Influence of membrane components on the stability and drug release properties of reverse-phase evaporation vesicles (REVs): light sensitive all-trans retinal, negatively charged phospholipid dicetylphosphate and cholesterol
SO Journal of Microencapsulation (1995), 12(6), 661-9
CODEN: JOMIEF; ISSN: 0265-2048

L3 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Nuernberg, Eberhard; Paspaleeva-Kuehn, Valentina
TI Polyoxyethylated detergents as vesicle components. Part 2
SO Pharmazie in Unserer Zeit (1995), 24(6), 331-8
CODEN: PHUZBI; ISSN: 0048-3664

L3 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Morikawa, Yasuri; Azuma, Kunio; Aono, Katsutoshi; Sasaki, Atsushi; Murahashi, Naoichi; Sakagami, Masahiro
TI Preparation of poly(ethylene glycol)-based lipid and glycolipids having acidic functional groups as micro-particle pharmaceutical carriers
SO Jpn. Kokai Tokkyo Koho, 58 pp.
CODEN: JKXXAF

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Jaeaeskelaeinen, Ilpo; Urtti, Arto
TI Liquid chromatography determination of liposome components using a light-scattering evaporative detector
SO Journal of Pharmaceutical and Biomedical Analysis (1994), 12(8), 977-82
CODEN: JPBADA; ISSN: 0731-7085

L3 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Uyama, Ichiro; Kumai, Koichiro; Yasuda, Tatsuji; Tagawa, Toshiaki; Ishibiki, Kyuya; Kitajima, Masaki; Tadakuma, Takushi
TI Improvement of therapeutic effects by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes
SO Japanese Journal of Cancer Research (1994), 85(4), 434-40
CODEN: JJCREP; ISSN: 0910-5050

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Liu, Dexi; Huang, Leaf
TI Interaction of pH-sensitive liposomes with blood components
SO Journal of Liposome Research (1994), 4(1), 121-41
CODEN: JLREE7; ISSN: 0898-2104

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Bagshawe, Kenneth Dawson
TI Inactivation of cytotoxic drugs in cytotoxic drug therapy, and prodrug therapy kit
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Jerome, Corbiere
TI Pharmaceutical liposomes containing peptides

SO Fr. Demande, 25 pp.
CODEN: FRXXBL

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Mori, Hideto; Nishikawa, Naoyuki
TI Preparation of isoprenoid phospholipids
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF

L3 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Chang, Tse Wen
TI Conjugates of liposomes or microbeads and antibodies specific for T-lymphocytes and their use as immunomodulators
SO Can. Pat. Appl., 33 pp.
CODEN: CPXXEB

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Park, Jung Hwan; Lee, Eun Ok; Kim, Jong Duk
TI Preparation and characteristics of phosphatidylcholine liposomes covalently coupled with immunoglobulin fragments
SO Yakche Hakhoechi (1992), 22(2), 115-24
CODEN: YAHAEX; ISSN: 0259-2347

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Sahasrabudde, Chintaman G.
TI Immunoliposomes for transmittal of activating signals to cells in vitro
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2

L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Fukuda, Masahiro; Okano, Tomomichi
TI Sulfofatty acid derivatives for manufacturing pharmaceutical liposomes
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF

L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Seid, Robert C., Jr.; Paradiso, Peter R.; Poolman, Jan T.; Hoogerhout, Peter; Wiertz, Emmanuel J. H. J.; Van der Ley, Peter; Heckels, John Edward; Clarke, Ian Nicholas
TI Meningococcal class 1 outer-membrane protein vaccine
SO PCT Int. Appl., 121 pp.
CODEN: PIXXD2

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Hibino, Hidehiko; Iwasaki, Hiroshi; Nakachi, Osamu
TI Preparation of phosphatidylcholines by acylation of glycerophosphocholine
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Miyaji, Hideki; Hokukoku, Shusaburo; Tomikawa, Munehiro; Hirota, Sadao; Kikuchi, Hiroshi
TI Preparation of mannobiose derivatives as liposome components
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW

L3 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Peeters, Pierre A. M.; Claessens, Conny A. M.; Eling, Wijnand M. C.; Crommelin, Daan J. A.
TI Immunospecific targeting of liposomes to erythrocytes
SO Biochemical Pharmacology (1988), 37(11), 2215-22
CODEN: BCPCA6; ISSN: 0006-2952

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN

AU Ikuta, Kazuyoshi; Ueda, Shigeharu; Uchida, Tsuyoshi; Okada, Yoshio; Kato, Shiro
TI Selective killing of human immunodeficiency virus-infected and -producing cells by liposomes containing diphtheria toxin fragment A
SO Japanese Journal of Cancer Research (1987), 78(11), 1159-63
CODEN: JJCREP; ISSN: 0910-5050

L3 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Sunamoto, Junzo; Sato, Tomonori; Ishii, Nobuko; Shoji, Toshihiko
TI Preparation of liposomes coated with polysaccharides and Fab' fragents of monoclonal antibodies as pharmaceutical carriers
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF

L3 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Vanlerberghe, Guy; Zysman, Alexandre; Seba, Henri
TI Cyclic alkoxy-substituted hemiacetals as carriers for reactive compounds and as components of liposomes
SO Ger. Offen., 47 pp.
CODEN: GWXXBX

L3 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Bredehorst, Reinhard; Ligler, Frances S.; Kusterbeck, Anne W.; Chang, Eddie L.; Gaber, Bruce P.; Vogel, Carl Wilhelm
TI Effect of covalent attachment of immunoglobulin fragments on liposomal integrity
SO Biochemistry (1986), 25(19), 5693-8
CODEN: BICHAW; ISSN: 0006-2960

L3 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Guo, Luke S. S.; Hamilton, Robert L.; Goerke, Jon; Weinstein, John N.; Havel, Richard J.
TI Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins
SO Journal of Lipid Research (1980), 21(8), 993-1003
CODEN: JLPRAW; ISSN: 0022-2275

=> d 15 18 bib ab l3

L3 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:548430 CAPLUS
DN 121:148430
TI Improvement of therapeutic effects by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes
AU Uyama, Ichiro; Kumai, Koichiro; Yasuda, Tatsuji; Tagawa, Toshiaki; Ishibiki, Kyuya; Kitajima, Masaki; Tadakuma, Takushi
CS Sch. Med., Keio Univ., Tokyo, 160, Japan
SO Japanese Journal of Cancer Research (1994), 85(4), 434-40
CODEN: JJCREP; ISSN: 0910-5050
DT Journal
LA English
AB To improve the therapeutic efficiency of adriamycin entrapped in antibody-conjugated liposomes, a Fab' fragment was used instead of the whole antibody mol. A murine monoclonal antibody, 21B2, against human carcinoembryonic antigen (CEA) was digested with pepsin, and the SH residue of the heavy chain produced by redn. of F(ab')2 with dithiothreitol was conjugated to liposomes contg. adriamycin. The tissue distribution of adriamycin delivered with these liposomes was studied in BALB/c nu/nu female mice bearing CEA-pos. human gastric cancer strain MKN-45. An increase in delivery of adriamycin to the tumor was obsd. in mice given liposomes with the Fab' fragment as compared to those given liposomes with the whole antibody. However, the preferential distribution

of liposome-borne adriamycin to the reticuloendothelial cells remained the same regardless of the use of Fab' fragment. For investigation of in vivo therapeutic effect, 3 i.v. injections of free adriamycin or of liposome-borne adriamycin (equiv. to 5 mg adriamycin/kg) were given; adriamycin in the Fab' fragment-conjugated liposomes was the most effective in the inhibition of tumor growth. This was confirmed in terms of actual tumor wts. excised and CEA concn. in the blood, as well as by pathol. observations. The advantages of using Fab' fragment instead of whole antibody are discussed.

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:656541 CAPLUS
DN 119:256541
TI Pharmaceutical liposomes containing peptides
IN Jerome, Corbiere
PA Fr.
SO Fr. Demande, 25 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2685868	A1	19930709	FR 1992-18	19920103
	FR 2685868	B1	19950623		
PRAI	FR 1992-18		19920103		

AB Pharmaceutical liposomes contg. peptides for oral or parenteral use are disclosed. Soya phosphatidylcholine, cholesterol, and dicetyl phosphate at a ratio of 7:2:1 were used to prep. liposomes contg. insulin which were filtered over Sepharose 6B and lyophilized.